GlassScriptPhysician profile
Katherine L Broering
NPI 1609142579
$2,069.45
in general payments reported to CMS, 2019-2025
23 companies · $411 in 2025
The $411 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $209 · 2021: $330 · 2022: $235 · 2023: $275 · 2024: $255 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $453.87 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $242.13 | 2020-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $205.48 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $199.44 | 2019-2025 | Bexsero, Arexvy |
| Cranial Technologies, INC | $140.82 | 2019-2025 | Doc Band |
| Corium, LLC | $118.29 | 2022-2025 | Azstarys |
| Boston Scientific Corporation | $111.83 | 2019 | |
| Collegium Pharmaceutical, INC. | $80.21 | 2025 | Jornay Pm |
| Pfizer INC. | $72.36 | 2022-2024 | |
| Genentech USA, INC. | $65.60 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $51.93 | 2022-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $46.57 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.81 | 2019 | |
| Verrica Pharmaceuticals INC. | $39.30 | 2024-2025 | Ycanth |
| Kaleo, INC. | $31.66 | 2022-2023 | Auvi-Q |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.11 | 2025 | |
| Tris Pharma INC | $24.86 | 2019 | |
| Alk-Abello, INC | $24.35 | 2025 | Neffy |
| Sanofi Pasteur INC. | $22.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.38 | 2019 | |
| Neos Therapeutics, LP | $15.64 | 2025 | Cotempla Xr-Odt |
| Ironwood Pharmaceuticals, INC | $15.30 | 2024 | |
| Shire North American Group INC | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Broering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.